Opthea Limited (NASDAQ:OPT - Get Free Report)'s stock price traded up 1.6% on Tuesday . The company traded as high as $4.00 and last traded at $3.93. 20,625 shares were traded during trading, a decline of 13% from the average session volume of 23,805 shares. The stock had previously closed at $3.87.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the stock. HC Wainwright cut their price target on shares of Opthea from $14.00 to $12.00 and set a "buy" rating for the company in a report on Tuesday, September 3rd. Canaccord Genuity Group upgraded shares of Opthea to a "strong-buy" rating in a research report on Tuesday, December 17th.
View Our Latest Stock Report on Opthea
Opthea Trading Up 1.6 %
The stock's fifty day simple moving average is $3.71 and its two-hundred day simple moving average is $3.22.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Opthea stock. Twin Lakes Capital Management LLC acquired a new position in Opthea Limited (NASDAQ:OPT - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 19,806 shares of the company's stock, valued at approximately $81,000. Institutional investors and hedge funds own 55.95% of the company's stock.
Opthea Company Profile
(
Get Free Report)
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Read More
Before you consider Opthea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.
While Opthea currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
